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1. Introduction 
The presence of muscarinic receptors in mammalian 
brain has been extensively demonstrated by binding 
experiments using various radioactive ligands (cf. [I]). 
Amongst those, [jH]dexetimide appeared to be a very 
appropriate ligand because of its pronounced stereo- 
specificity, its very high affinity and its slow dissocia- 
tion properties [2-41. The solubilization of muscarinic 
receptors from mammalian brain has been successfully 
achieved by treating tissue with high salt concentration 
(NaCl, 2 N) [5-71 or with the natural detergent 
digitonin [2]. In these studies, the use of [3H]propyl- 
benzilycholine mustard, [3H]atropine and [3H]dexe- 
timide as ligands, with the aid of equilibrium dialysis 
and nitrate cellulose filtration techniques made it 
possible to isolate the ligand-receptor complex. 
Although various biochemical properties have been 
determined for salt and detergent extracts a character- 
ization of the muscarinic receptor by means of sedi- 
mentation centrifugation has never been described. 
We now report some biochemical and pharma- 
cological properties of a digitonin-solubilized complex 
from rat brain which was isolated by means of an 
improved gel-fdtration technique [8,9] and sedimen- 
tation gradient using either [3H]dexetimide or [3H]- 
levetimide as ligands. The receptor protein revealed a 
single peak (9 S) after centrifugation and was identical 
to the membrane preparation in its affinity for various 
drugs. 
2. Materials and methods 
Male and female Wistar rats (& 250 g) were decap- 
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itated and the brains were immediately removed. The 
forebrain was rapidly dissected and placed in ice-cold 
sucrose (0.25 M). The tissue was then homogenized 
and fractionated as in [lo]. The resulting microsomal 
fraction (P) was suspended in 1 vol. ice-cold water 
and kept at -16°C. 
2.1. Solubilizatiorz procedure 
Digitonin (Serva) suspension, 1 vol 2%, in phos- 
phate buffer (NaH2P04-Na2 HP04,20 mM, pH 7.2) 
containing 0.02% NaN,, was added to aliquots of the 
P fraction. The mixture was gently agitated for 15 min 
and centrifuged at 120 000 X g for 1 h. The super- 
natant, henceforth called the solubilized preparation 
(about 2 mg protein/ml), was carefully removed using 
a Pasteur pipette without disturbing the pellet. The 
whole procedure was carried out at 0°C. 
2.2. Binding procedure 
Solubilized preparations were incubated with [3H]- 
dexetimide (spec. act. 17 Ci/mmol, IRE, Fleurus) in 
the nM range and various concentrations of unlabelled 
drug in total vol. 0.5 ml. Specific [3H]dexetimlde 
binding was defined as the difference between the 
binding in the presence of levetimide (L-benzetimide) 
and dexetimide (D-benzetimide) at concentrations 
which were loo-times higher than the labelled ligand. 
In some cases [3H]levetimide (spec. act. 19 Ci/mmol, 
IRE) was also used as radioactive ligand. A 0.1 ml 
aliquot of the incubation mixture was placed on the 
top of a Sephadex G-50 Medium (Pharmacia) column 
(13 X 0.5 cm) [8,9] which was carefully cooled to 
‘-3°C. The elution was carried out using a constant 
rate pump system (13 drops/min) with cold phos- 
phate buffer, 10 mM, pH 7.2, containing 0.1% digitonin. 
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Four-drop fractions were collected in counting vials 
and the radioactivity was measured in a Packard liquid 
scintillation spectrometer. 
2.3. Sucrose gradient centrifigation 
After incubation with [3H]dexetimide 0.2 ml soluble 
extract ( -2 mg protein/ml) was layered on the top of 2 800- 
a gradient of 5-20% sucrose buffered with 10 mM b 
sodium phosphate, pH 7.2, and supplemented by 
8 
0.03% digitonin. It was then centrifuged at 2-3°C in 
Iso0 
t 
a SW 65 Ti rotor (Spinco, Beckman) at 40 000 rev./ ! i 
min for 16 h. 
-Z 
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2.4. Protein and enzymatic assa_vs 
Protein was estimated by the method in [ 111. 
Dopa decarboxylase (DDC) and dopamine-fl-hydrox- 
ylase (DPH) from bovine adrenal medulla were esti- 
mated as in [ 121. /3-Galactosidase (PC) from E. coli 
(Aldrich), malate dehydrogenase (MDH) from pig 
heart, lactate dehydrogenase (LDH) from rabbit 
muscle and catalase (CTL) from bovine liver (Boehringer) 
were assayed according to different procedures 
[13-161. Finally the acetylcholinesterase activity was 
detected in rat brain extracts by hydrolysis of S-ace- 
tylthiocholine [ 171. 
1:ig.l. Gel-filtration elution patterns of solubilized prepara- 
tions at various protein concentrations (a, b, c) after incuba- 
tion with (3H]dexetimide (10.’ M) in the presence of 10e6 M 
levetimide ( ---) or dexetimide (- - -). The inset shows the 
linear relationship of bound [‘Hldexetimide with increasing 
protein concentration. 
3. Results and discussion 
As shown in fig.1 a good separation between the 
[3H]dexetimide bound macromolecular complex (first 
peak) and the free radioactive drug (second peak) was 
obtained with the gel-filtration procedure. After incu- 
bation in the presence of unlabelled drug, the first 
peak disappeared entirely, indicating that the t3H]- 
dexetimide binding is displaceable. Moreover the 
bound [3H]dexetimide was not affected by incubation 
with lo-’ M neostigmine bromide, a powerful inhibitor 
of acetylcholinesterase. By comparing the number of 
binding sites in the microsomal fraction and in the 
solubilized preparation, the extraction yield was 
found to vary from 5-l 2%. 
The [3H]dexetimide binding to solubilized prepa- 
rations was stereospecific (fig.2A) as has been found 
for membrane preparations [2,4]. Indeed the displace- 
ment curve obtained for the active enantiomer of 
benzetimide (dexetimide, ICsO 1.4 X 10e9 M) mark- 
edly differed from that with the inactive enantiomer 
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(levetimide, ICsO 5.6 X 1 Od6 M). This 4000-fold dif- 
ference between optical isomers is quite compatible 
with that obtained in membrane preparations. Further 
evidence of stereospecificity was produced using [3H]- 
levetimide. First the binding value obtained with the 
inactive ligand was markedly lower than that with 
the active ligand. Secondly the displacement curves 
for both enantiomers of benzetimide were similar and 
very flattened (fig.2B), indicating the non-specific 
nature of this binding. 
In addition, a good correlation was obtained between 
the ZCsO values of various muscarinic agonists and 
antagonists, in the soluble and membrane rat brain 
preparations (table 1). The competition curves of 
agonists with the digitonin-solubilized preparation 
were monophasic as was also observed for the salt- 
soluble extract [7]. From the foregoing experiments 
it is clear that the solubilized [3H]dexetimide-receptor 
complex was undoubtedly of a muscarinic nature, 
because all the drugs tested revealed the same relative 
affinity in solubilized or membrane preparations [4] 
and in the pharmacological test [18]. 
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600- 
[31-t]-DEXETIMIDE (Al Figure 3 shows that the [3H]dexetimide binding is 
saturable in the same range as the membrane prepa- 
ration [4]. The Scatchard analysis gave a linear rela- 
tionship mdicating a single class of binding site. Further 
the dissociation constant (Ka =S X tO_” M) obtained 
using solubilized preparation is closely related to that 
measured with the corresponding membrane prepara- 
tion (/Cd = 6.5 X lo-” M). 
Cevetwnide 
Interestingly, the soluble preparation displayed a 
much higher sensitivity to thermal inactivation than 
the menlbrane preparation [4]. Indeed after 5 min 
& 1 
0 
z 300- [3H]-LEVETIMIDE 
I 
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Fig.2. Inhibition curves of both cnantiomers of benzetimide 
using (A) [3H]deuefimide (2 X low9 M) and (B) [3H]leve- 
timide (2 X lo-’ M) in solubilized preparations. 
l:ig.3. Saturation curve and Scatchard plot of the (3H]deae- 
timide binding in a solubilized preparation. 
Table 1 
Comparison between the IC,, values of [Wjdexctnnide (2 X 1O-9 IV) binding 
using soluble and membrane [3,4] preparations and the ED,, values of 
antisecretory activity in the pilocarpine-test in rats [ 181 
Binding IC,, (M) Pharmacological 
__~ ..- activity ED,, (me/k?) 
Solubte Membrane 
Dexetimide 
Atropine 
Trihexyphenidyl 
Levetimide 
O~otrcmor~ne 
Carbamylcholine 
1.4 x 1o-9 2.8 x IO.“’ 0.02 
2.8 x 1O-9 6.8 x 1o-9 0.12 
7.9 x lo-* 2.1 x 10-a 0.50 
5.6 x 10-e 6.5 x 1O-6 > 2.5 
5.6 x 1O-6 6.5 X IO-’ _ 
3.5 x 1o-5 3.2 X 1O‘4 _ 
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cated that 83% of the maximal binding value was 
reached after incubation at 0°C for 7 h, but the disso- 
3 E 5m- ciation rate in the presence of a lOO-fold greater con- 
” 
hf 
centration of unlabeiled drug was noteworthy slow. 
2 ‘W- 
2 
Under these experimental conditions the binding of 
[3H]dexetimide with soluble muscarinic receptor 
5 WI- 
Y 
revealed an extremely slow dissociation rate, a prop- 
x erty which makes this ligand very appropriate for 
D zoo- 
J further ultracentrifugation experiments. 
4 Figure SA shows that when a solubilized prepara- 
Vx- tion was incubated with [3H]dexetimide and then 
submitted to sedimentation through a sucrose gradient 
04 -+ - 0 i 2 3 1 s 6 7 a high peak of radioactivity appeared approximately 
TIME (h0”,Sl in the middle of the tube, indicating the presence of a 
Fig.4. Time course of [ %jdeuetimldc binding (-) at 
0°C In a solubillzed preparation and its dissociation (- - -) in 
the presence of a lOO-fold excess of unlabelled dexetimide 
(2 x 1O-7 M). 
incubation at 56”C, only 17% of the original binding 
capacity was found whereas under the same conditions, 
95% was still present in the membrane preparation. 
The time course of association at 0°C (fig.4) indi- 
[3H]dexetimide-bound macromolec~ar complex. In 
contrast to this the radioactivity remained at the top 
when the incubation was performed in the presence 
of an excess of unlabelled dexetimide. A different 
distribution pattern (fig.SB) was obtained for the 
acetylcholinesterase, indicating that [3H]dexetimide 
macromolecular complex was not associated with 
the enzyme. Moreover the enzyme activity was corn. 
pletely inhibited by 5 X 10e6 M neostigmine bro- 
mide without affecting the Z3H]dexetimide binding. 
f 1 
FRACTION NUMBER 
Fig.5. (A) Distribution profile of [3H]dcxetimlde after centrifugation of a solubihzed preparation incubated with 2 X 1O-9 M of 
the l&and in the presence of 2 X lo-’ M (-*a-) levetimide and (-o-c-o-) dexetimide. (B) Sedimentation of bound [3H]dexetimide 
(-*-o-o-) compared to that of acetylcholinesterase (-& -.-A-). (C) Sedimentation profile of the soiubie [3H]dexetimide macromolec- 
ular complex and various marker enzymes. 
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In order to estimate the sedimentation coefficient 
of the [3H]dexetimide-receptor complex, the distri- 
bution profile of various marker enzymes was deter- 
mined after centrifugation in a sucrose gradient. 
Figure 5C shows that the [3H]dexetrmide-receptor 
complex sedimented in an area located between D/3H 
and LDH. From the known sedimentation coefficient 
of the different marker enzymes [ 19-231, one can 
estimate that the sedimentation coefficient of the 
muscarinic receptor labelled with [3H]dexetimide is 
-9 S, a value which is in agreement with -200 000 
mol. wt. A more precise measure cannot yet be made 
because, as emphasized [ 19-21,24,25], macromolec- 
ular complexes extracted from membranes were often 
asymmetric structures and were also associated with 
large amounts of lipids, two parameters affecting the 
physico-chemical and particularly the hydrodynamic 
properties of biomacromolecules. Furthermore, the 
9 S digitonin-solubilized muscarinic receptor appeared 
to have a more complex structure than that obtained 
by the NaCl 2 N extraction (30 000 mol. wt) [5,6]. 
Therefore, the present experiments show that [3H]- 
dexetimide is a particularly appropriate ligand for the 
isolation of muscarinic receptors. Indeed its proper- 
ties enabled us to characterize by means of gel-tiltra- 
tion as well as by sedimentation centrifugation a 
digitonin-solubilized macromolecular complex which 
is endowed with all the characteristics found in the 
original membrane preparation. 
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